Trials / Completed
CompletedNCT01175590
Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle
A Study to Evaluate the Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle Following Three Times Daily(TID) Dosing for 7 Days
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 518 (actual)
- Sponsor
- Bausch & Lomb Incorporated · Industry
- Sex
- All
- Age
- 1 Year
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate the safety of Besivance (besifloxacin ophthalmic suspension, 0.6%) compared to vehicle.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Besivance | Ocular administration to affected eye for 7 days |
| DRUG | Vehicle | Vehicle of Besivance administered to affected eye for 7 days |
Timeline
- Start date
- 2010-06-01
- Primary completion
- 2011-12-01
- Completion
- 2012-02-01
- First posted
- 2010-08-05
- Last updated
- 2013-05-01
- Results posted
- 2013-05-01
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01175590. Inclusion in this directory is not an endorsement.